Karen Knudsen named AAACI president-elect

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Karen Knudsen, enterprise director of the Sidney Kimmel Cancer Center–Jefferson Health, was elected vice president/president-elect of the Association of American Cancer Institutes’ board of directors.

Knudsen, who has been serving as SKCC enterprise director since 2015, governs cancer research and cancer care across 14 hospitals within Jefferson Health.

Under Knudsen’s leadership, SKCC recently was evaluated as “Outstanding” in its most recent NCI Cancer Center Support Grant renewal. It was one of only three cancer centers to rank “Exceptional” by the NCI for Community Outreach and Engagement.

Knudsen is also the Hilary Koprowski Chair, Department of Cancer Biology at Thomas Jefferson University, and Professor of Cancer Biology, Urology, Medical Oncology, and Radiation Oncology. Her translational research centers on prostate cancer and has contributed to new mechanisms for treatment of advanced disease.

A member of AACI’s board of directors since 2016, Knudsen was program chair of the association’s 2017 annual meeting. She also serves on review, advisory, and elected panels for the NIH, Department of Defense, American Society of Clinical Oncology, American Association for Cancer Research, and is editor-in-chief of the journal Molecular Cancer Research.

Knudsen’s two-year term will begin Sept. 30 during the AACI/Cancer Center Administrators Forum annual meeting in Chicago.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login